Takeda to Acquire URL Pharma
- Details
- Category: Takeda
Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma - a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.
UCB marks World Parkinson's Disease Day with new Parkinson's Well-Being Map™
- Details
- Category: UCB
UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map™ is a visual tool designed to help people with PD discuss their health status and well-being with their care teams.
Amgen to acquire privately held KAI Pharmaceuticals
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.
Open-source drug research consortium draws a major new champion
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (Takeda) has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. The SGC is based at the Universities of Toronto, Canada, and Oxford, England.
Roche sends second letter to Illumina shareholders
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche's increased offer and vote for Roche's independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche's increased offer.
Neupro® approved by U.S. FDA for Parkinson's disease and Restless Legs Syndrome
- Details
- Category: UCB
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro® (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
More Pharma News ...
- Amgen and AstraZeneca announce collaboration to jointly develop and commercialize clinical-stage inflammation portfolio
- Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines
- Bayer HealthCare and Beijing's Tsinghua University extend innovative drug discovery partnership
- Sanofi and Regeneron report phase 2 data for potential first-in-class lipid-lowering PCSK9 antibody
- US court denies preliminary injunction application against the FDA and dismisses AstraZeneca's lawsuit
- Roche's Herceptin given by subcutaneous injection offers greater convenience and reduces costs
- UK court finds SEROQUEL XR® formulation patent invalid